Skip to main content
. 2023 Jul 11;10:891. Originally published 2021 Sep 6. [Version 2] doi: 10.12688/f1000research.51073.2

Table 2. Patient demographics and baseline characteristics.

Parameter Placebo
(n = 363)
Methylnaltrexone Total
(N = 1263)
SC
(n = 298)
Oral
(n = 602)
All
(n = 900)
Mean age, years (range) 51.3 (23, 83) 48.3 (23, 78) 51.3 (18, 82) 50.3 (18, 82) 50.6 (18, 83)
Gender, n (%)
Men 134 (36.9) 120 (40.3) 227 (37.7) 347 (38.6) 481 (38.1)
Women 229 (63.1) 178 (59.7) 375 (62.3) 553 (61.4) 782 (61.9)
Race, n (%)
White 307 (84.6) 272 (91.3) 494 (82.1) 766 (85.1) 1073 (85.0)
Black or African American 42 (11.6) 17 (5.7) 93 (15.4) 110 (12.2) 152 (12.0)
Other 14 (3.9) 9 (3.0) 15 (2.5) 24 (2.7) 38 (3.0)
Median baseline MED, mg/day (range) 145.3 (13.6, 1287) 160.0 (7.1, 1334) 151.0 (27.0, 2289) 152.5 (7.1, 2289) 150.0 (7.1, 2289)
Mean number of laxatives used (SD) 0.4 (0.6) 0.9 (0.5) 0.1 (0.4) 0.4 (0.5) 0.4 (0.6)
Mean RFBMs per week (SD) 1.3 (1.0) 1.0 (0.8) 1.4 (0.9) 1.3 (0.9) 1.3 (0.9)
Mean pain score (SD) 6.2 (1.9) 6.2 (1.9) 6.4 (1.9) 6.3 (1.9) 6.3 (1.9)

MED = morphine equivalent dose; RFBM = rescue-free bowel movements; SC = subcutaneous; SD = standard deviation.